Use of IL-12 antagonists in the treatment of conditions promoted by an increase in levels of IFN-y
US6706264B1 · kind B1 · utility
7Cited by
12References
15Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 25, 2000 |
| Grant date | Mar 16, 2004 |
| Priority date | — |
| Expiry date | Feb 25, 2020 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/76
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Method of treating autoimmune conditions are disclosed comprising administering to a mammalian subject IL-12 or an IL-12 antagonist. In certain preferred embodiments the autoimmune condition is one which is promoted by an increase in levels of IFN-&ggr; or TNF-&agr;. Suitable conditions for treatment include multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, autoimmune pulmonary inflammation, Guillain-Barre syndrome, autoimmune thyroiditis, insulin dependent diabetes melitis and autoimmune inflammatory eye disease.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.